Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and it can lead to liver cancer. | Microbiology ...

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity.” Not long after, study first ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity." Not long after, Dr. Prescott ...

Use the tweezers to pull out a segment of DNA from the hepatitis B virus. A subunit vaccine makes use of just a small portion of a pathogen. For a virus, the vaccine can contain just a piece of ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Seroconversion from HBeAg to anti-HBe is usually associated with serum HBV DNA undetectable by hybridization technology and remission of liver disease. Nevertheless, a certain proportion of anti ...

Occult HBV infection is defined by the existence of HBV DNA in serum, lymphoid cells (PBMC) and/or the liver and virus-genome replicative intermediates (i.e., covalently closed circular DNA ...

and integrated DNA These PBGENE-HBV data mark the second clinical validation for ARCUS in vivo gene editing in 2025 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing ...